{'fraction_non_alphanumeric': 0.01977401129943503, 'fraction_numerical': 0.01694915254237288, 'mean_word_length': 6.23469387755102, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population

The drug‐metabolizing enzymes and transporters (DMET) Plus microarray and x‐Tag assays have recently been developed for genotyping individuals in personalized medicine. Furthermore, the cytochrome 450‐2C19 (CYP2C19) is a key metabolic enzyme encoded by a polymorphic gene commonly associated with diminished metabolism and variable clinical responses to several drugs in an ethnicity‐dependent fashion. Therefore, validation of these clinical procedures as well as knowledge of the ethnic‐specific incidences of these gene variants is prerequisite for determining their clinical relevance in any given population.